Research Article
The Diagnostic and Prognostic Value of Cardiac Magnetic Resonance Strain Analysis in Heart Failure with Preserved Ejection Fraction
Table 1
Baseline clinical characteristics.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Continuous variables were presented as mean ± SD or median (Q1, Q3). Category variables were presented as n (%). eGFR (estimated glomerular filtration rate) = 175 × creatinine − 1.234 × age − 0.179 × 0.79 (if female); value <0.05 was considered statistically significant. . Abbreviations: HFpEF, heart failure with preserved ejection fraction; BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; NYHA, New York Heart Association; CHD, coronary heart disease; MI, myocardial infarction; AF, atrial fibrillation; PAH, pulmonary arterial hypertension; T2DM, type 2 diabetes mellitus; DAPT, dual antiplatelet therapy; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CRP, C-reactive protein; NT-proBNP, N-terminal pro–B-type natriuretic peptide; HbA1c, glycated hemoglobin; TC, total cholesterol; TG, total triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein. |